ALT · Altimmune, Inc.
$2.67
-0.07 (-2.38%)
At close · Oct 5
Return incl. dividend (before tax)
Market Cap
$575.77M
Shares
194.52M
Volume · Oct 5
3.84M
Avg daily vol (3M)
4.14M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$2.67
Open$2.73
Day$2.65–2.75
52W close$2.59–6.18
Avg vol 30d3.7M
Short int51.7M · 26.6% float · 15.4d
Short vol74%
Last earningsAug 12, 2026
DataJan 2020–Oct 2026
Filing10-Q · Aug 12
Up next
Next earnings call
Oct 24, 2026
Est · unconfirmed
· in 3 wks
filed Aug 12, 2026
call held Aug 12, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
—
Year over year · more shares
Price change (1Y)
-30.4%
Trailing year
Short interest
26.6%
Latest settlement · 15.4 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Bullish
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 15.5 · calm
Equity put/call 0.59
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−23%
below
Price vs 50-day avg
−13%
below
RSI (14)
29
oversold
MACD trend
Negative
52-week position
2%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−22%
trailing
6-month return
−19%
trailing
YTD return
−26%
this year
Relative strength
−30%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $3 › 200d $3 — 200d above 50d
Institutional flow
Accumulating
1 of 211 funds reported for Sep 30 · net +176 sh shares
Insider flow
Accumulating
Net +$44.3K over 90 days · 0% sells
Short interest
Rising
26.60% of float · ▲ +4.1% MoM · 15.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
211 holders — near 3-yr high, broad support
Squeeze score
77
high risk · 0–100
Fundamentals
Revenue growth
+105%
Y/Y
EPS growth
+25%
Y/Y
Free cash flow
$-67.5M
Balance sheet
$9.5M
net cash
Quant / Vol
risk profile
Volatility
69%
annualized · 1-yr
Max drawdown
−58%
past year
ATR
5.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−23%
Bearish
Price vs 50-day avg
−13%
Bearish
RSI (14)
29
Neutral
MACD trend
Negative
Bearish
52-week position
2%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $3 › 200d $3 — 200d above 50d
Institutional flow
Accumulating
1 of 211 funds reported for Sep 30 · net +176 sh shares
Insider flow
Accumulating
Net +$44.3K over 90 days · 0% sells
Short interest
Rising
26.60% of float · ▲ +4.1% MoM · 15.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
211 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $3
Now $3 · 2%
Range high $6
vs 200-day avg -23%
vs 50-day avg -13%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ALT
this stock
Altimmune, Inc.
|
$575.77M | -26.0% | +105.0% | — | 26.6% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +11.1% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -5.9% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +589.1% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ALT | -9.8% | -21.9% | -18.8% | -6.6% | -26.0% |
| SPY | +1.2% | +0.6% | +11.6% | +1.6% | +13.6% |
| vs SPY | -11.0% | -22.5% | -30.4% | -8.2% | -39.7% |